MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
54.39
-0.26
-0.48%
After Hours: 54.64 +0.25 +0.46% 19:57 07/17 EDT
OPEN
54.10
PREV CLOSE
54.65
HIGH
54.69
LOW
53.76
VOLUME
2.57M
TURNOVER
--
52 WEEK HIGH
86.74
52 WEEK LOW
40.03
MARKET CAP
8.99B
P/E (TTM)
-25.8852
1D
5D
1M
3M
1Y
5Y
1D
Cathie Wood Just Bet Big on This Biotech Stock
The Motley Fool · 19h ago
Ionis (IONS) Begins First ION337 Trial In Dravet Syndrome Patients
Simply Wall St · 1d ago
Ionis Pharmaceuticals: The Heartbreak Is Priced In
Seeking Alpha · 2d ago
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 2d ago
Ionis Pharmaceuticals Cut to Peer Perform From Outperform by Wolfe Research
Dow Jones · 2d ago
Wolfe Research Downgrades Ionis Pharmaceuticals to Peer Perform
Benzinga · 2d ago
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data
TipRanks · 3d ago
Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
TipRanks · 3d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.